StockData

Korsana Biosciences vs Xenon Pharmaceuticals

KRSA and XENE side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.

How KRSA and XENE compare

Xenon Pharmaceuticals is the larger company, worth 25 times as much as Korsana Biosciences ($3.8B against $152M).

Korsana Biosciences grew revenue faster over the last twelve months (−12.6% versus −100% for Xenon Pharmaceuticals).

Xenon Pharmaceuticals scores higher on the StockData Score (7 against 6 for Korsana Biosciences), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.

Key numbers

A dot marks the better figure where higher or lower is clearly better.

MetricKRSAXENE
Size and price
Market cap$152M$3.8B
Share price$32.50$38.78
Change, 1 year241%−4.9%
Change, 5 years−90.5%41.3%
Beta (5Y)5.730.26
Employees1370
StockData Score
Total score67 (better)
Valuation score00
Growth score1 (better)0
Performance score11
Health score46 (better)
Dividend score00
Valuation
P/S80.1×–
P/B29.9×3.0× (better)
FCF yield–−9.0%
Fair value$5.48–
Margin of safety−493%–
Growth
Revenue growth (TTM)−12.6% (better)−100%
Revenue growth, 5Y average−2.0% (better)−25.3%
Profitability
Operating margin−359%–
Net margin−353%–
Return on equity−98.2%−43.6% (better)
Return on invested capital−116% (better)−152%
Financial health
Debt / equity0.000.00
Current ratio0.8221.02 (better)
Altman Z-score−9.2540.35 (better)
Piotroski F-score33
Dividends and buybacks
Shareholder yield0.00%0.00%
Ownership
Held by institutions15.1%104%
Held by insiders–0.17%
Insider net buying, 12 months–−$20.3M
Superinvestors holding–1
Short interest, % of float–7.6%

Go deeper

For information only, not investment advice. Check the source filings before relying on any figure.